Stockreport

CorMedix Outlines Post-Melinta Growth, Q2 REZZAYO Phase 3 Catalyst and DefenCath Reimbursement Shift [Yahoo! Finance]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF adds REZZAYO , with a global Phase 3 prophylaxis readout expected in Q2 that could expand the label beyond treatment (current treatment TAM ~$250–$350M) if fungal-free s [Read more]